The immune response after streptococcal infections of the skin and of the joints was studied in an experimental animal model. Hamsters were challenged intradermally or intra-articularly with different streptococcal serotypes, and antibodies for streptolysin 0 (ASO), deoxyribonuclease B (anti-deoxyribonuclease B), and group A carbohydrate (anti-group A CHO) were determined. After a single injection at either site, 7 of 48 animals (14%) developed group A-CHO antibodies; however, none of the animals developed detectable levels of ASO or anti-deoxyribonuclease B. After repeated infections of the skin or joint, anti-deoxyribonuclease B antibodies were detectable in 13 % (4 of 30) and 30% (5 of 17) of the animals, respectively. Elevations of ASO occurred after repeated joint infections in 4 of 16 animals (25%), whereas none of 30 hamsters repeatedly infected intradermally developed antibodies against streptolysin 0. For all three antibodies tested, elevated levels were more frequently noted after repeated joint infections than after repeated skin infections with the same streptococcal serotype. These data, similar to ones previously noted in human impetigo, indicate that ASO responses are feeble after streptococcal skin infections and that the site of infection per se, rather than the infecting strain, appears to be responsible for this poor response.
Variations in the immune response to different streptococcal antigens have been observed as related to the site of infection in humans (12) . Rises in anti-streptolysin 0 (ASO) are slight in patients with streptococcal skin infections (6, 9, 11, 12) , and antibodies to streptococcal nicotinamide adenine dinucleotidase occur irregularly in these patients (9) . In contrast, anti-streptococcal deoxyribonuclease B (anti-deoxyribonuclease B) titers are regularly, and often markedly, elevated after streptococcal pyoderma (6, 9) . Antibodies to all of these streptococcal products occur more consistently in patients with streptococcal pharyngitis (12) .
The Syrian hamster has been used by us to study various aspects of experimental impetigo (2) (3) (4) (5) . The disease in the hamster simulates human impetigo in gross appearance, in the progression of the lesions in various stages, and in the histopathology of the process (3) . During the course of these studies, no type-specific protection was detected in animals repeatedly infected with the same streptococcal serotype (3) . The present studies were designed to assess the effect of the site of infection on antibody response to different streptococcal antigens in the hamster. (2) (3) (4) (5) .
Animal inoculation. Experimental impetigo was produced in the hamsters as previously described (3) . Each animal was injected at four sites by using 106 colony-forming units of the various organisms contained in 0.1 ml of a broth culture. Attempts at producing respiratory infection with group A streptococci in this animal were unsuccessful after intranasal instillation and throat inoculation of all strains used. However, septic arthritis could be reproducibly effected in hamsters after intra-articular injection of 0. To investigate the effect, if any, of the site of infection on the subsequent development of antibodies against the streptococcal products or components, an additional group of 17 hamsters was infected intra-articularly with M-type 57 streptococci. The animals were infected on three successive occasions with a 3-week interval between challenges. Four weeks after the last infection all animals were bled. The results of the antibody titers on these animals are shown in Fig. 2 . Five of the 17 hamsters exhibited elevated anti-deoxyribonuclease B titers. Of the 16 sera available for ASO determinations, 4 demonstrated an elevation. All but one of the 15 sera tested for group A CHO antibody showed levels of 0.10 or greater. The one animal that showed no group A CHO antibody elevation failed to respond to streptolysin 0 and deoxyribonuclease B also. Among the four animals with elevated ASO titers, two had simultaneous anti-deoxyribonuclease B elevations.
Comparison of the antibody elevations as related to the site of repeated infection is summarized in Table 2 . For all three antibodies, titers were much more frequently elevated after repeated joint infections as compared with repeated skin infections. Of the 30 animals infected intradermally, 13 (43%o) showed an elevation of one or more antibody. In marked contrast, 14 of the 15 animals (93 %) infected intra-articularly demonstrated such elevations. 
DISCUSSION
Several studies have amply documented that the ASO titer is not a reliable serological test for the retrospective diagnosis of streptococcal pyoderma in man (6, 9, 11, 12) . The results of the present studies indicate that ASO responses also vary in the hamster in relation to the site of infection. Respiratory infection with group A streptococci could not be produced in this animal, but septic arthritis occurred consistently after intraarticular injection. Although arthritis in the animal model may not be optimally comparable to pharyngitis in humans, the differences between lrr) lao L- (9, 12) . Although streptococcal strains are known to vary in production of various extracellular products (13) , such variance in production of streptolysin 0 is probably not responsible for the dichotomy of ASO responses between skin and throat infections. During an epidemic period (9) when a single streptococcal strain (M-type 49) was responsible for most of the infections of both the skin and the respiratory tract, ASO responses were significantly higher in patients who had respiratory and skin infections than in those with skin infections alone. Furthermore, in the present studies, the same streptococcal strain was injected intradermally or intra-articularly, yet differences in the ASO levels were noted between these two groups.
That the site of infection per se, rather than the infecting strain, may be the determining factor for this disparity of the ASO response is a reasonable assumption based on the experimental data presented here and previous clinical reports (9, 12) . Conditions on or in the skin may not be optimal for streptolysin 0 production. Some lipids, notably cholesterol, inhibit streptolysin 0 activity both in vitro and in vivo (1). It is possible that skin lipids may interfere with the antigenicity of streptolysin 0, resulting in a poor ASO response. Additional work is warranted to examine this possibility.
